Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05562024 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 27, 2023 (before its estimated December 18, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Start date changed from estimate of Dec 15, 2022 to Dec 30, 2022 · Interventions: T cell injection targeting FLT3 chimeric antigen receptor (Biological) to T cell injection targeting B7-H3 chimeric antigen receptor (Biological) · 1 morev3 Show 4 more changesShow less
    • Study sites: 1 to 2
    • Start date changed from estimate of Dec 15, 2022 to Dec 30, 2022
    • Interventions: T cell injection targeting FLT3 chimeric antigen receptor (Biological) to T cell injection targeting B7-H3 chimeric antigen receptor (Biological)
    • Collaborators expanded, about 12 words

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: Oct 18, 2022 to Dec 15, 2022 Study site revisedv2 Show 1 more changeShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase I clinical trials are designed as open-label, dose-escalation and dose-expansion clinical studies, the main purpose of which is to explore the tolerability, safety, cytokinetic characteristics and RP2D and preliminary observation of the efficacy of the study drug in subjects with B7-H3-positive relapsed/refractory neuroblastoma.
Trial Details
NCT Number NCT05562024
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators: Tianjin Medical University Cancer Institute and Hospital, Shandong Cancer Hospital and Institute
Conditions B7-H3-positive Relapsed/ Refractory Neuroblastoma
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov